Lab-Quality Quantitative Results— In Just 2–5 Minutes
We enable gastroenterologists to make treatment decisions in less than 5 minutes—without compromising lab-quality results.
This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
We enable gastroenterologists to make treatment decisions in less than 5 minutes—without compromising lab-quality results.
Our point-of-care platform combines speed, simplicity, and accuracy to transform patient care in real time.
A finger-prick sample and minimal staff training is all you need. No complex lab infrastructure required.
Total turnaround time is only 2 to 5 minutes. Every minute matters during a patient appointment.
Central-lab quality, sensitivity, and specificity. Healthcare professionals don’t have to sacrifice accuracy for speed.
We are revolutionizing point-of-care diagnostics by enabling gastroenterologists to make real-time, data-driven treatment decisions. With the rise of TNFα therapies for Inflammatory Bowel Disease (IBD), consistent monitoring is essential to optimize patient outcomes.
Our proprietary drug monitoring assays deliver lab-quality results from a fingerprick whole blood sample in under 5 minutes—empowering clinicians to adjust therapy during the patient visit.
“With ProciseDx, we will be able to measure levels of infliximab and adalimumab in five minutes from fingerstick blood. This information during the patient visit will be incorporated into our immediate treatment decisions.”
Leveraging time-resolved Förster Resonance Energy Transfer (tr-FRET) detection and patented chemistry, ProciseDx delivers rapid, quantitative immunoassays with unmatched precision.
Instrument and CRP now FDA Cleared. Other assays not yet available for sale in the United States.
Our growing portfolio of quantitative immunoassays supports precision medicine in gastroenterology and beyond.
Monitor therapeutic levels of infliximab in IBD patients.
Quantify adalimumab levels for personalized IBD therapy.
Inflammatory marker for monitoring disease activity.
Monitor gut-selective biologic therapy levels.
Support dosing decisions for IL-12/23 inhibitor therapy.
Comprehensive panel for multiple biologics.
Detect immunogenicity to biologic therapies.
Non-invasive marker of intestinal inflammation.
September 2023 – The CRP immunoassay is now FDA cleared, expanding the platform’s capabilities in inflammation monitoring.
August 2023 – Data confirms high correlation with central lab methods, supporting real-time decision-making in IBD care.
To learn more about ProciseDx or speak with our team, please visit our official website.
Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact [email protected] via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系[email protected] 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact [email protected]
如果您是其他域名合作 也请联系[email protected]